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Abstract
Background: Cysteine protease cathepsins are important in extracellular matrix protein degradation, cell apoptosis, and
angiogenesis. Mice lacking cathepsins are protected from tumor progression in several animal models, suggesting that the
regulation of cathepsin activities controls the growth of various malignant tumors.
Methods and Results: We tested the role of cathepsins using a mouse model of multistage epithelial carcinogenesis, in
which the human keratin-14 promoter/enhancer drove the expression of human papillomavirus type 16 (HPV16) early
region E6/E7 transgenes. During the progression of premalignant dysplasia, we observed increased expression of cysteine
protease cathepsin S, but concomitantly reduced expression of cathepsin endogenous inhibitor cystatin C in the skin tissue
extract. Absence of cystatin C in these transgenic mice resulted in more progression of dysplasia to carcinoma in situ on the
face, ear, chest, and tail. Chest and ear skin extract real time PCR and immunoblot analysis, mouse serum sample ELISA,
tissue immunohistological analysis, and tissue extract-mediated in vitro elastinolysis and collagenolysis assays demonstrated
that cystatin C deficiency significantly increased cathepsin expression and activity. In skin from both the chest and ear, we
found that the absence of cystatin C reduced epithelial cell apoptosis but increased proliferation. From the same tissue
preparations, we detected significantly higher levels of pro-angiogenic laminin 5-derived c2 peptides and concurrently
increased neovascularization in cystatin C-deficient mice, compared to those from wild-type control mice.
Conclusion: Enhanced cathepsin expression and activity in cystatin C-deficient mice contributed to the progression of
dysplasia by altering premalignant tissue epithelial proliferation, apoptosis, and neovascularization.
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Introduction
Cysteine protease cathepsins are secretory lysosomal proteases
that mediate both intracellular and extracellular protein degrada-
tion. Besides degrading endocytosed unwanted proteins, cathep-
sins are critical in degrading extracellular matrix collagen, laminin,
fibronectin, and elastin, thus playing essential roles in tumor
growth [1,2]. Secreted and cell membrane–bound forms of tumor
cathepsins may relate to local cellular behavior in certain cancers
[3,4]. Studies have described increases in cathepsin levels for most
invasive cancer types [5]. In cancers, the best-studied cathepsins
include cathepsins B (CatB), L (CatL), and S (CatS). In an
immunohistological study using samples from human colon cancer
patients, CatB was overexpressed and correlated strongly with
angiogenesis and regional lymph node metastasis [6]. CatB
inhibition in glioblastoma cells via RNA interference (RNAi)
resulted in impaired invasion, reduced cell–cell interaction with
endothelial cells (EC), disruption of capillary network formation in
vitro and in vivo, and inhibition of established glioma tumor growth
and invasion in intracranial tumors in vivo [7,8]. RNAi-mediated
CatB inhibition also reduced meningioma cell migration and
invasion and led to significant regression of pre-established
orthotopic tumors [9]. In an ischemic hindlimb model, CatL-
deficient mice showed reduced neovascularization. CatL-deficient
EC were less able to support the vascularization at the site of
ischemia than were wild-type EC [10]. Transfection of an anti-
CatL single-chain variable fragment in human melanoma cells
inhibited the tumorigenic and metastatic properties completely,
therefore producing less angiogenic and smaller tumors [11].
Similar observations were made in a RIP-Tag2 transgenic mouse
pancreatic islet cell carcinoma model, in which the rat insulin II
promoter (RIP) drove expression of the SV40 large T-antigen
(Tag). These tumors also had increased cathepsin expression,
which associated with angiogenic vasculature along the invasive
front. Reduction in the activity of cathepsins using the pharma-
cologic inhibitor JPM, or deficiency of CatS, impaired angiogenic
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vascularity, and invasiveness [12,13].
Cystatins are endogenous inhibitors of cysteinyl cathepsins.
Cathepsin to cystatin ratio increases in most tumor types,
compared to normal tissue, particularly for advanced cancers
[14–17]. Cystatin C, the most important, abundant, and widely
expressed cathepsin inhibitor in humans and animals, decreased
with concomitant increase of CatB in high-grade gliomas [15].
Benign ovarian cancers had significantly higher cystatin C levels
than did malignant tumors [17]; in prostate cancers, cystatin C
levels also decreased at late stages [18]. Nearly 50% of cancers
show decreased expression of cystatin C, and perhaps of other
cystatins [19]. However, tumor cystatin levels vary widely. In
prostate cancers, cystatin C levels remained high at early stages
[18]. During colorectal cancer progression, cystatin C remained
unchanged between stages, whereas CatB levels remained high at
any stage [20]. Serum cystatin C levels are significantly higher in
patients with ovarian cancers than in benign ovarian tumors or in
healthy women, though serum CatB levels are not different [21].
Similar findings are observed in patients with head and neck
squamous-cell carcinoma; serum cystatin C levels in these patients
are higher than those from control groups [22]. These observa-
tions suggest that the relative ratio of cystatin C to cathepsins in
tumor tissues in situ, and not solely the proteases or inhibitors or
those in the circulation, are essential in regulating tumor growth.
One approach to directly evaluate the effect of cystatin C on
tumor initiation and evolution uses animal models with either
increased or decreased expression of this inhibitor. More than 10
years have passed since the generation of the first cystatin C–
deficient mouse to test its function in cancers. When melanoma
cells were injected intravenously, cystatin C–deficient lungs
showed reduced metastasis, but subcutaneous growth of melano-
ma cells was not different from that in control mice [23]. In
contrast, cystatin C overexpression was associated with decreased
glioblastoma cell invasion in vitro and tumor growth in vivo [24].
Such overexpression caused higher apoptosis in vivo for metastatic
melanoma cells [25], and dramatically blocked lung metastasis of
human fibrosarcoma cells (,90%) in mice [26]. To date, however,
there has been no rigorous experimental examination of how this
cathepsin inhibitor participates in tumor growth.
In this study, we introduced cystatin C mutant alleles into the
invasive epidermis multistage squamous-cell carcinoma (SCC)
mouse model [27], in which the human keratin-14 promoter/
enhancer drove the expression of human papillomavirus HPV16
early region genes, including the E6/E7 oncogenes, to test
whether absence of this dominant cathepsin inhibitor alters the
progression of premalignant dysplasia. This established dysplasia
to carcinoma model [27] is characterized by temporally and
histopathologically reproducible, multi-stage progression of dys-
plasia by 3 months to SCC by 9 months. Accordingly, it is ideal for





2/2) mice (C57BL/6/S129 back-
ground) [23] were backcrossed to an FVB/n background (Jackson
Laboratories, Bar Harbor, ME) for .5 generations. These mice
were crossbred with K14-HPV16 transgenic mice [27] (kindly
providedbyDr.LisaCoussenfromtheUniversityofCalifornia,San
Francisco), in the same FVB/n genetic background to ensure early-
stage (at 3 months) dysplasia. K14-HPV16 transgenic Cstc
2/2 and
Cstc
+/+ wild-type littermates were sacrificed at 3 months of age.
Chest and ear skin were collected and immediately embedded in
compound OCT (optimum cutting temperature) for frozen section
preparation (6 mm) or pulverized in liquid nitrogen to prepare tissue
extracts for protein (lysed in a pH 5.5 buffer containing 1% Triton
X-100, 40 mM sodium acetate, and 1 mM EDTA) or total RNA
(lysed in TRIzol reagent; Stratagene, La Jolla, CA) preparation.
To test CatS and cystatin C expression during the progression
of hyperplasia and dysplasia, we harvested skin tissues from K14-
HPV16 transgenic mice at 1 month, 3 months, and 6 months of
age for immunoblot analysis. Due to severe skin premalignant
dysplasia from the K14-HPV16 transgenic Cstc
2/2 mice after 3
months of age, we were unable to study mice beyond this time
point, for compliance with the humane standard of the Animal
Research Committee of Harvard Medical School (approved
animal protocol number 03759).
Real-time PCR
Real-time polymerase chain reaction (RT-PCR) was used to
determine cathepsin transcript levels, including CatK, CatL, CatS,
and CatB, in both chest skin and ear skin from 3-month-old K14-
HPV16 transgenic Cstc
+/+ and Cstc
2/2 mice. Total cellular RNA
was extracted from TRIzol reagent-treated tumor tissue extracts.
RNase-free DNase (Ambion, Austin, TX) was used to remove
genomic DNA contaminants. Equal amounts of RNA were reverse-
transcribed, and quantitative PCR was assessed in a single-color
RT-PCR detection system (Stratagene). The level of each cathepsin
transcript was normalized to that of the b-actin transcript.
Western blot
Protein concentration of each tumor extract in pH 5.5 buffer
was determined using Bio-Rad DC protein assay kit (Bio-Rad,
Hercules, CA). An equal amount of protein (30 mg/sample) of
each tissue extract preparation was separated on 14% SDS-PAGE,
followed by immunoblot analysis with rabbit anti-human cathep-
sins S, L, and K polyclonal antibodies (1:1000, Calbiochem, San
Diego, CA) or rabbit anti-human cystatin C polyclonal antibodies
(1:1000; DAKO Corp., Carpinteria, CA), all of which cross-
reacted with mouse gene products. Goat anti-mouse b-actin
polyclonal antibodies (1:5000, Santa Cruz Biotechnology, CA)
were used to determine equal protein loading. Densitometry
analysis (ImageJ software, Bethesda, MD) was used to determine









for CatS, matrix metalloproteinase-9 (MMP-9) (R&D Systems, Inc.,
Minneapolis, MN), and CatL (Bender MedSystems Inc., Burlin-
game, CA) were used according to the manufacturers’ protocols.
Collagenase and elastase activity assay
A total of 20 mg of chest and ear skin extract from K14-HPV16
transgenic Cstc
+/+ and Cstc
2/2 mice was combined to a final
volume of 100 ml in EDTA-containing pH 5.5 buffer that was
optimized for measuring cysteinyl cathepsin activities, but not
MMPs or other neutral serine proteases. Fluorogenic elastin
(10 mg/well, DQ elastin, Invitrogen, Carlsbad, CA) or type I
collagen (10 mg/well, Calbiochem) were added to a 96-well plate.
After adding 3 mM of dithiothreitol (Sigma, St. Louis, MO), the
plate was incubated at 37uC for 3 days and read at an excitation of
505 nm and emission of 515 nm. Data were presented as relative
fluorescent units.
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Frozen sections (6 mm) prepared from chest and ear skin of the
K14-HPV16 transgenic Cstc
+/+ and Cstc
2/2 mice were used for
conventional histological (hematoxylin and eosin stain) and
immunohistological analysis with rabbit anti-human CatS poly-
clonal antibody (1:170, cross-reacts with mouse CatS) [28]; rabbit
anti-human Ki67 polyclonal antibody (1:750, NovoCastra Labo-
ratories Ltd, Newcastle, UK); rat anti-mouse CD31 (1:150), Mac-3
(1:900), CD4 (1:90), and CD8 (1:100) monoclonal antibodies
(Pharmingen, San Diego, CA); rabbit anti-mouse laminin 5
fragment c2 polyclonal antibody (1:250) [29]; and the TUNEL
staining kit (ApopTagH Plus Peroxidase In Situ Apoptosis Kit,
Millipore, Billerica, MA). Immunostaining was analyzed using
computer-assisted image analysis software (Image-Pro Plus; Media
Cybernetics, Bethesda, MD). Data were presented as antigen-
positive area (%) or cell number per mm
2.
Statistical analysis
Due to our relatively small sample sizes and abnormal data
point distribution, we used the non-parametric Mann-Whitney U
test to examine the statistical significance for all data in this study.
All data were presented as mean 6 SEM. P,0.05 was considered
statistically significant.
Results
Cystatin C and CatS expression in early hyperplasia and
dysplasia stages from K14-HPV16 transgenic mice
As discussed, expression of cathepsins and their inhibitors varies
at different stages of tumor growth [22]. To examine whether
CatS and cystatin C were also expressed differently during the
progression of premalignant dysplasia, we collected chest skin
tumor tissues at different stages from K14-HPV16 transgenic mice
that were wild-type for cystatin C, including those tumors
established at early (3 months) and late (6 months) stages of
dysplasia. Immunoblot analysis demonstrated that CatS protein
levels plateaued at 3,6 months of age. Normal skins or those from
the early stage (e.g., 1 month) had negligible CatS proteins
(Figure 1A). In contrast, normal skins had high levels of cystatin C
protein, which then decreased during premalignant progression,
although cystatin C protein did not completely disappear at the 3-
month and 6-month progression stages (Figure 1B).
Cystatin C deficiency enhanced SCC in K14-HPV16
transgenic mice
To test the effect of cystatin C in SCC, we introduced the K14-
HPV16 transgene into Cstc
2/2 and Cstc
+/+ littermate control mice
by crossbreeding Cstc
2/2 mice [23] with K14-HPV16 transgenic
mice [27]. Genomic DNA PCR confirmed the cystatin C
genotypes in K14-HPV16 transgenic mice (data not shown).
Due to the extent of malignant dysplasia in Cstc
2/2 K14-HPV16
transgenic mice at later time points (after 3 months), for humane
purposes, we sacrificed the K14-HPV16 transgenic mice that were
Cstc
+/+and Cstc
2/2 at 3 months of age for the remainder of the
study. Anti-human cystatin C polyclonal antibody–mediated
immunoblot analysis of chest skin tissue extracts from 3-month-
old Cstc
2/2 and Cstc
+/+ K14-HPV16 transgenic mice confirmed
the absence of cystatin C in Cstc
2/2 mice (Figure 1C). At the 3-
month time point, we observed SCC formation that was clinically
more pronounced in skin from the chest (Figure 2A), tail
(Figure 2B/C), face, and ear (Figure 2D/E) from the Cstc
2/2
mice as compared with that of the Cstc
+/+ mice. These differences
were confirmed histologically (Figure 2F–I); whereas back and ear
skin from Cstc
+/+ mice exhibited dysplasia (nuclear atypia and
disordered maturation in epidermal cells, primarily within the
lowermost layers), abnormalities were present uniformly through-
out a thickened and more hyperkeratotic epidermal layer in the
Cstc
2/2 mice, thus qualifying for a designation of SCC in situ. Such
SCC formation or dysplasia was absent in Cstc
2/2 or Cstc
+/+ mice
without the K14-HPV16 transgene (not shown). Therefore,
absence of cystatin C enhanced dysplasia to SCC progression in
site-matched skin in the K14-HPV16 transgenic mice.
Cystatin C deficiency increased cysteinyl cathepsin
expression and activities
Enhanced SCC formation in Cstc
2/2 K14-HPV16 transgenic
mice compared with those wild-type for cystatin C suggests the
importance of this endogenous cathepsin inhibitor in early tumor
progression in vivo. The development of SCC in Cstc
2/2 K14-
HPV16 transgenic mice possibly results from altered counterbal-
ance between cystatin C and cathepsins. To test this hypothesis,
we prepared total RNA from chest and ear skin and performed
RT-PCR. Absence of cystatin C significantly increased the RNA
levels of cathepsins L, S, and B in the chest skin and of CatL in the
Figure 1. Immunoblot analysis for CatS and cystatin C in mouse
chest skin tissue extracts. Chest skin tissue extracts from K14-HPV
transgenic Cstc
+/+ mice at different stages (1 month, 3 months, and 6
months) were analyzed for CatS (A) and cystatin C (B) expression.
Cystatin C immunoblot analysis confirmed the absence of cystatin C in
K14-HPV transgenic Cstc
2/2 mice in chest skin tissue extracts from 3-
month-old K14-HPV transgenic Cstc
+/+ and Cstc
2/2 mice (C). Equal
protein loading (30 mg/lane) was confirmed with a b-actin immunoblot.
doi:10.1371/journal.pone.0013973.g001
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using protein samples from the chest skin (Figure 3C) or the ear
skin (Figure 3D) also revealed significantly increased CatS protein
in the chest skin extracts (Figure 3E) and CatK and CatL proteins
in the ear skin extracts (Figure 3F), as determined by densitometric
measurements. In serum from K14-HPV16 transgenic Cstc
+/+ and
Cstc
2/2 mice, we made similar observations. Serum from the
Cstc
2/2 mice had significantly higher levels of both CatS
(Figure 4A) and CatL (Figure 4B) than that from the Cstc
+/+
mice, whereas cystatin C deficiency did not significantly affect
serum MMP-9 levels (Figure 4C). Chest and ear skin immunohis-
tological analysis also revealed increased expression of CatS
throughout the epidermis and dermis from Cstc
2/2 mice,
compared with those from Cstc
+/+ mice (Figure 5).
Absence of cystatin C also enhanced tumor tissue extract
cathepsin activities. Upon incubating chest and ear skin extracts in
pH 5.5 buffer, which measures only cysteinyl cathepsins [30], with
fluorogenic elastin and collagen, two common matrix protein
substrates for cathepsins S, L, K, and B, we found that tumor
tissue extracts from both the chest skin and ear skin from Cstc
2/2
mice had significantly higher elastase (Figure 6A) and collagenase
(Figure 6B) activities than those from Cstc
+/+ mice. Together, our
data demonstrated increased expression and activities of cysteinyl
cathepsins in the absence of cystatin C.
Tumor progression often accompanies inflammatory cell
infiltrations [31–33], including monocytes/macrophages, B and
T lymphocytes, NK cells, and neutrophils. These infiltrates often
influence the tumor progression directly. For example, in the same
Figure 2. Enhanced epidermal dysplasia in cystatin C-deficient K14-HPV16 transgenic mice. Premalignant dysplasia on 3-month-old K14-
HPV16 transgenic Cstc
+/+ and Cstc
2/2 mouse chest skin (A), tail (B, C), face, and ear (D, E). Mouse genotypes are indicated. Histopathology of lesions
from Cstc
+/+ and Cstc
2/2 mice (F, H, and G, I, respectively) taken from chest skin (F, G) and ear skin tissue (H, I), showing partial-thickness atypia of
epidermal cells in Cstc
+/+ mice, and full-thickness atypia (double headed arrow, SCC in situ)i nCstc
2/2 mice. Both dermis and epidermis are indicated.
Also note that SCC in Cstc
2/2 mice extends to involve the adnexal epithelium of hair follicles (horizontal arrow).
doi:10.1371/journal.pone.0013973.g002
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+/+ and Cstc
2/2 mouse chest (A)
and ear (B) skin tissue real-time PCR analysis for cathepsins K, L, S, and B. Number of mice per group is indicated in each bar. C/D: K14-HPV16
transgenic Cstc
+/+ and Cstc
2/2 mouse chest (A) and ear (B) skin tissue extract immunoblot analysis for cathepsins K, L, and S. Actin immunoblots were
used for protein loading controls. E/F: Densitometric analysis for the cathepsin immunoblot signals from the chest (E) and ear (F) shown in C and D.
Data are mean 6 SEM. p,0.05 was considered statistically significant, non-parametric Mann-Whitney U test. NS: no significant difference.
doi:10.1371/journal.pone.0013973.g003
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CD4
+ T cells delays neoplastic progression and lowers tumor
incidence [33]. These cells are rich in cathepsin expression and
activities [34,35]. Therefore, increased cysteinyl cathepsin expres-
sion and activities in SCC chest and ear skin tissues from Cstc
2/2
mice can be the results of the absence of cystatin C as well as of
enhanced inflammatory cell infiltration. To examine this hypoth-
esis, we immunostained both the chest and ear sections from
Cstc
+/+ and Cstc
2/2 mice for CD4, CD8, and macrophage marker
Mac-3. Both chest and ear sections from Cstc
2/2 mice contained
significantly higher percentages of CD4-positive areas than did the
Cstc
+/+ mice (Figure 7A). Mac-3–positive areas were also higher in
the ear sections, but not in the chest sections, from Cstc
2/2 mice
than from Cstc
+/+ mice (Figure 7B). There were no differences,
however, in CD8-positive areas in chest sections (10.5364.35 vs.
8.4063.44, P=0.252) and ear sections (6.3763.79 vs. 7.3460.56,
P=0.096) between Cstc
2/2 and Cstc
+/+ mice. Increased infiltration
of CD4
+ T cells and Mac-3
+ macrophages in Cstc
2/2 mice may
account in part for enhanced lesion cathepsin activities in chest
and ear skin from these mice (Figures 3C–3F, 5, and 6).
Decreased apoptosis and increased cell proliferation in
cystatin C–deficient SCC
Tumor cell apoptosis and proliferation are major determinants
of growth or progression of cancers [36,37]. The development of
fully evolved in situ SCC in Cstc
2/2 mice, but not in Cstc
+/+ mice,
suggests that cystatin C deficiency may reduce tumor cell apoptosis
and/or increase tumor cell proliferation. To test this possibility, we
immunostained both the chest and ear skin tissue frozen sections
for TUNEL and for the cell proliferation marker Ki67. Consistent
with our hypothesis, tumor tissues (chest and ear skin) from Cstc
2/2
mice had significantly fewer total apoptotic cells than those from
Cstc
+/+ mice(Figure 8A). In Cstc
+/+ mouse chest skin, most apoptotic
cells were noted in the epidermis and hair sebaceous unit areas.
Figure 4. Serum protease levels. Serum levels of CatS (A), CatL (B), and MMP-9 (C) in K14-HPV16 transgenic Cstc
+/+ and Cstc
2/2 mice. Number of
mice per experimental group is indicated in each bar. Data are mean 6 SEM. NS: no significant difference.
doi:10.1371/journal.pone.0013973.g004
Figure 5. Immunostaining for CatS in chest and ear skin tumor sections. Number of mice per experimental group is indicated in each bar.
Representative sections are shown to the right. Both dermis and epidermis (ED) are indicated. Data are mean 6 SEM. Data are presented as % of CatS-
positive area. Scale bar: 100 mm.
doi:10.1371/journal.pone.0013973.g005
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Cstc
2/2 mouse chest skin, both the epidermis and sebaceous unit
showed noteworthy reduction of apoptotic cells. In contrast,
apoptotic cells from the Cstc
+/+ mouse ear skin clustered in the
dermis, while ear skin from the Cstc
2/2 mice had significantly
reduced levels of such apoptotic cells (Figure 8A). Significantly more
Ki67-positive proliferating cells were identified in the epidermis and
sebaceous units from chest skin of the Cstc
2/2 mice than in those
from the Cstc
+/+ mice (Figure 8B). Reduced apoptosis, but increased
proliferation in the epidermis and sebaceous unit of Cstc
2/2 mice,
thus correlates withprogression to SCC in situ. Similar findings were
documented in the Cstc
2/2 mouse ear skin. In the epidermis of
Cstc
2/2 mouse ear skin, we detected significantly more Ki67-
positive cells than in that of the Cstc
+/+ mice (Figure 8B). In
summary, cystatin C deficiency increased cell proliferation but
decreased cell apoptosis, thus correlating with progression toSCCin
situ in both chest and ear skin, events that likely also developed at
other similarly affected sites (e.g., tail and face skin; Figure 2).
Cystatin C deficiency led to increased angiogenesis
Cysteinyl cathepsin-mediated angiogenesis is important in
cancer progression and tumor growth. We reported that in the
pancreatic islet cell carcinoma RIP-Tag2 model, absence of CatS
significantly reduced tumor growth [13]. Mechanistically, we
demonstrated that CatS mediates extracellular matrix laminin-5
degradation, followed by the production of a pro-angiogenic
peptide from laminin-5 proteolysis, named c2 [13,29]. In CatS-
deficient mice, along with reduced tumor growth, we detected
significant reduction of this c2 fragment, and concomitantly,
greatly impaired angiogenesis [13]. Along with producing the c2
fragment from laminin-5, cysteinyl cathepsins mediate other
matrix protein degradation, all of which relate to angiogenesis
and tumor growth. In the present study, we conjectured that the
absence of cystatin C caused increased cathepsin expression and
activities (Figures 3–6) and enhanced pro-angiogenic c2 produc-
tion with promotion of angiogenesis, leading to increased
progression to SCC (Figure 2). To test this hypothesis, we
Figure 6. Mouse chest and ear skin tissue extract elastase and collagenase assays. K14-HPV16 transgenic Cstc
2/2 mouse chest and ear skin
tissue extracts showed significantly increased elastase (A) and collagenase (B) activities compared those of the Cstc
+/+ mice. Number of mice per
group is indicated in each bar. Data are mean 6 SEM.
doi:10.1371/journal.pone.0013973.g006
Figure 7. Immunostaining for inflammatory cells in chest and ear skin tumor sections. CD4
+ T cells (A) and Mac-3
+ macrophages (B)i n
K14-HPV16 transgenic Cstc
+/+ and Cstc
2/2 mouse chest and ear skin tissue sections. Number of mice per group is indicated in each bar.
Representative sections are shown to the right. Both dermis and epidermis (ED) are indicated. Data are mean 6 SEM. Scale bar: 100 mm.
doi:10.1371/journal.pone.0013973.g007
Cystatin C and Dysplasia
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13973performed immunohistological analysis of both chest and ear skin
from the Cstc
+/+ and Cstc
2/2 mice. Consistent with our hypothesis,
we detected significantly more c2-positive microvessels in the
dermis of both chest and ear skin of Cstc
2/2 mice than in those of
Cstc
+/+ mice (Figure 9A). Along with increased c2 production in
Cstc
2/2 mouse chest and ear skin, we observed significant
enhancement of CD31-positive microvessels in the skin of these
mice, more than twice as many as those from Cstc
+/+ mice
(Figure 9B). Increased angiogenesis in Cstc
2/2 mouse skin may
relate to associated progression to SCC.
Discussion
Protease and protease inhibitor counterbalance prove physiolog-
ically important and pathologically relevant in human diseases.
Increasedproteaseactivities,eitherbyincreased proteaseexpression
or decreased protease inhibitor expression, lead to many common
human disorders, such as cardiovascular diseases, metabolic
conditions, bone metabolic dysfunction, cancers, and neurological
complications. We have previously shown that the absence of
cystatin C enhanced atherogenesis in apolipoprotein E-deficient
(Apoe
2/2) mice [38]. One mechanism of advanced atherogenesis in
these Apoe
2/2 mice, increased cathepsin activities, leads to
enhanced elastinolysis and collagenolysis, and thus to blood-borne
leukocyte accumulation in the neointima. In the present study,
although using a different disease model, we found that cystatin C
deficiency results in enhanced SCC progression involving a similar
mechanism to what we have observed in the cardiovascular system.
Absence of this cathepsin inhibitor enhanced cathepsin expression
and activity, which altered epidermal cell kinetics and advanced
angiogenesis, thereby expediting cancer progression.
The function of cathepsins in angiogenesis has been well studied
in several disease models [39]. In general, angiogenesis involves
extensive extracellular matrix protein degradation and tissue
remodeling, which requires protease involvement. But cathepsins
can achieve more than just matrix protein degradation. In vitro
studies showed that CatB and CatL can liberate collagen IV,
laminin, and fibronectin from the basement membrane, generate
gelatinolytic fragments, and initiate a ‘‘metastatic cascade,’’
thereby promoting angiogenesis and tumor invasion [40]. We
recently have shown that CatS degrades the anti-angiogenic
peptides arresten, canstatin, and tumstatin, all of which constitute
collagen IV degradation products [13,41]. Further, CatS degrades
the natural basement membrane matrix protein laminin-5, and
generates pro-angiogenic c2 fragments in vitro [13,29]. Cysteinyl
cathepsin proteolysis of these latent matrix proteins therefore is
Figure 8. Immunostaining for apoptotic and proliferating cells in chest and ear skin tumor sections. K14-HPV16 transgenic Cstc
+/+ and
Cstc
2/2 mouse chest and ear skin tissue section immunostaining for TUNEL (A) and Ki67 (B). Representative sections are shown in the right panels.
Dermis and epidermis (ED) are indicated. Arrowheads indicate hair sebaceous units. Data are mean 6 SEM. Scale bar: 100 mm.
doi:10.1371/journal.pone.0013973.g008
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we found in the CatS-deficient RIP-Tag2 model. Absence of CatS
reduced c2 fragment production, and consequently reduced islet-
cell carcinoma growth [13]. In the present study, we also detected
significantly higher amounts of CatS (Figure 5) and CatS-derived
laminin-5 c2 fragments (Figure 9A) in chest and ear skin lesions
from Cstc
2/2 mice than in those from Cstc
+/+ mice. These
observations furnish a mechanistic explanation of the increased
angiogenesis detected from the chest and ear skin of the Cstc
2/2
mice, compared with those from the Cstc
+/+ mice (Figure 9B).
Cancer cell proliferation and apoptosis closely relate to
angiogenesis, and therefore are important in tumor growth.
Angiogenesis provides cancer cells with sufficient nutrients for
survival and proliferation; reduced angiogenesis thus may cause
cancer cell apoptosis or decreased cell proliferation. In return,
cancer-cell apoptosis and proliferation can also regulate angio-
genesis. Cysteinyl cathepsins can participate importantly in these
processes. When co-cultured with human glioblastoma cells,
human microvascular EC increased the invasiveness of the
glioblastoma cells. On the other hand, glioblastoma cells
stimulated microvascular EC proliferation, which CatB-selective
inhibitor CA074me can impair [42]. Therefore, increased
expression of CatB may enhance EC proliferation in vivo. Although
we saw increased expression of several important cathepsins and
enhanced cancer cell proliferation in chest and ear skin sections
from Cstc
2/2 mice (Figure 8B), whether the increase of
proliferation associated with angiogenesis remains unknown.
Our observation of reduced cancer-cell apoptosis in chest and
ear skin from Cstc
2/2 mice (Figure 8A) gives some support to this
hypothesis.
Although we anticipated enhanced angiogenesis and tumor
growth in Cstc
2/2 mice, several aspects of our results remain
unexplained, and more studies are required for further under-
standing of the role of cathepsins in tumorigenesis. First, we
frequently have seen that absence of one protease affects the
expression of the others — for example, vascular cells from serine
protease chymase-deficient [43] or tryptase-deficient (unpublished
data) mice express significantly reduced levels of cathepsins. We
demonstrated in this study that deficiency of cystatin C increased
both RNA and protein levels of most, if not all, tested cathepsins.
Second, cathepsins are thought to promote cell apoptosis — for
example, CatB cleaves the anti-apoptotic protein Bcl-2 member
Bid and creates a pro-apoptotic signal of mitochondrial cyto-
chrome C release [44]. Osteosarcoma cell line U2OS, overex-
Figure 9. Immunostaining for microvessels in chest and ear skin tumor sections. K14-HPV16 transgenic Cstc
+/+ and Cstc
2/2 mouse chest
and ear skin tissue section immunostaining for laminin-5 fragment c2 (A) and CD31 (B). Number of mice per experimental group is indicated in each
bar. Representative sections are shown in the right panels. Dermis and epidermis (ED) are indicated. Data are mean 6 SEM. Scale bar: 100 mm.
doi:10.1371/journal.pone.0013973.g009
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p21, undergoes apoptosis in a CatB-dependent but caspase-
independent manner. CatB-selective inhibitor CA074me signifi-
cantly blocked U2OS cell death [45]. Thus, CatB-deficient mice
showed reduced cerebral cell losses, whereas a cystatin mutation
resulted in increased apoptosis of cerebellar granule cells [46]. A
direct role for cathepsins in promoting apoptosis does not explain
our finding in this study of increased cathepsin expression and
activities, but reduced cancer apoptosis (Figures 3–6, Figure 8A).
One possibility is that increased cathepsin expression and activities
in Cstc
2/2 mice enhanced extracellular matrix processing, which
may explain why we detected more laminin-5 fragment c2
(Figure 9A) and increased angiogenesis (Figure 9B). Compared
with the chest and ear skin from Cstc
2/2 mice, we found
significantly lower numbers of microvessels in the Cstc
+/+ mice
(Figure 9B). Reduced angiogenesis in Cstc
+/+ mice may affect
nutrient supply, thus increasing cell death and reducing prolifer-
ation, although a detailed mechanism of cathepsin function in this
SCC cancer model requires further investigation. Third, it is
conceivable that angiogenesis is essential for tumorigenesis after
angiogenic switch, but less so in early stages. Our data
demonstrated that enhanced cathepsin expression expedited
malignant transformation, which also can be caused by alterations
in growth factor levels, inflammatory cell infiltration (Figure 7),
and associated intracellular signaling. Mechanisms in addition to
enhanced angiogenesis may account for more advanced tumor-
igenesis in Cstc
2/2 mice than in Cstc
+/+ mice.
In conclusion, this study provides additional in vivo evidence to
support direct participation of cysteinyl cathepsins in tumor
growth. Based on these findings, we conjecture that the absence of
cystatin C also may increase the progression and growth of other
types of tumors. Thus, inhibition of cysteinyl cathepsins, either by
small molecular inhibitors [47], antibody therapy [48], or
retrovirus-mediated cathepsin inhibitor delivery [49], holds
potential for the development of novel cancer therapies.
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